- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 23.05. | The Platform Group - Strong momentum in Q125 | 495 | The Platform Group's Q125 results show strong momentum with a seasonally high adjusted EBITDA margin. Coming so soon after the recent FY24 results, there is no change to management's guidance for the... ► Artikel lesen | ||
| 23.05. | Smiths News - New recycling MD underpins new activity potential | 300 | Smiths News' PBT increased by 11% in H125, a combination of higher profits and lower financing costs as both debt and debt margins declined. However, in addition to this and perhaps more exciting is... ► Artikel lesen | ||
| 23.05. | Games Workshop Group - Strong core in Q425 | 457 | Games Workshop Group's year-end (2025) trading update shows a better Q4 than we expected, notably in its core business with high operational gearing. Licensing revenue and profit are broadly in line... ► Artikel lesen | ||
| 23.05. | BB Biotech - Optimistic about biotech's long-term prospects | 954 | During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution... ► Artikel lesen | ||
| 22.05. | OSE Immunotherapeutics - Strategic collaboration in mRNA technologies | 270 | OSE Immunotherapeutics has announced a new strategic collaboration with Inside Therapeutics and MiNT Laboratory (University of Angers) to develop mRNA therapies and accelerate nanodrug development.... ► Artikel lesen | ||
| 22.05. | Herantis Pharma - Dedicated to disease modification for PD | 262 | Herantis is striving to develop disease-modifying treatments for central nervous system (CNS) conditions, with an initial focus on Parkinson's disease (PD). Lead asset HER-096 has a novel mechanism... ► Artikel lesen | ||
| 21.05. | Basilea Pharmaceutica - Zevtera hits the shelves in the US | 332 | Basilea Pharmaceutica has announced the launch of Zevtera, its lead anti-bacterial treatment, in the US by partner Innoviva Specialty Therapeutics (IST), marking a key strategic milestone for the company.... ► Artikel lesen | ||
| 21.05. | ProCredit Holding - Investments starting to level off | 569 | ProCredit Holding (PCB) reported a Q125 annualised return on equity (ROE) of 9.5%, broadly in line with management's reiterated FY25 guidance of around 10% but down from 13.4% in Q124, as the company's... ► Artikel lesen | ||
| 21.05. | Carr's Group - Attractive options for cash or remain invested | 253 | Carr's Group's tender offer provides shareholders with the option to realise cash from the recent disposal of the Engineering division and/or remain invested in a refocused specialist agricultural group.... ► Artikel lesen | ||
| 21.05. | Greggs - Better trading conditions, easing comparative | 294 | Greggs' AGM trading update indicates an improvement in revenue growth in recent months versus a relatively weak start to the year, as management notes better trading conditions, while the market context... ► Artikel lesen | ||
| 21.05. | 4imprint Group - Holding steady against uncertain backdrop | 309 | 4imprint's AGM statement outlines flat revenues year-on-year for the first four months, with order intake levels running around 2% down and stable average order values. We view this as a respectable... ► Artikel lesen | ||
| 20.05. | Canyon Resources - Additional funding from core shareholder | 242 | On 19 May, Canyon Resources announced that it has received an option exercise notice from its key shareholder Eagle Eye Asset Holdings (EEA). EEA will exercise 350m options, resulting in cash proceeds... ► Artikel lesen | ||
| 20.05. | Borussia Dortmund - Timed to perfection | 444 | Borussia Dortmund's strong Q325 results reflect a relatively busy football schedule with just under one-half of the cumulative home games of the season played in the period. It is safe to say the most... ► Artikel lesen | ||
| 20.05. | Topps Tiles - Back to revenue and profit growth | 284 | The key takeaways from Topps Tiles' (TPT's) H125 results are: 1) there is meaningful progress on the Mission 365 initiatives announced one year ago; 2) the company is back into revenue and profit growth... ► Artikel lesen | ||
| 19.05. | Deutsche Beteiligungs - Stay tuned for more in 2025 | 607 | Deutsche Beteiligungs' (DBAG's) investment activity in Q125 was limited to one closed private equity (PE) investment (replacing external financing at an existing holding) and one private debt investment... ► Artikel lesen | ||
| 19.05. | Tinexta - Confident in rebound | 293 | The most important takeaway from Tinexta's Q125 results, which are typically a seasonally small part of full-year profits, is that management believes there are tangible signs of rebound by Cyber Security... ► Artikel lesen | ||
| 19.05. | Georgia Capital - Strong portfolio at a substantial discount | 258 | Georgia Capital (GCAP) delivered a solid NAV total return of 11.2% in Q125 in local currency terms (9.8% in GBP), continuing its strong 15.1% growth per annum since end-2018. Q125 NAV growth was driven... ► Artikel lesen | ||
| 19.05. | Claranova - Transition to pure play software business ongoing | 344 | Claranova's Q325 revenue update confirmed that Avanquest generated modest year-on-year growth, with profitability continuing to improve for the Security and PDF product lines. The group restructuring... ► Artikel lesen | ||
| 19.05. | Filtronic - Expanding presence in European space market | 305 | Filtronic has been awarded a contract to develop and supply filter and diplexer assemblies to Airbus for use in Eutelsat OneWeb low Earth orbit (LEO) satellites, with delivery expected in CY26. The... ► Artikel lesen | ||
| 19.05. | Oryzon Genomics - Preparations in place for an active 2025 | 267 | Q125 saw Oryzon make significant headway towards Phase III for vafidemstat in BPD and clinical advancement for iadademstat across multiple early-stage studies. Operating performance was unsurprising... ► Artikel lesen | ||
| 19.05. | Immix Biopharma - Steady progress in Q125 | 266 | Immix Biopharma's Q125 results reflect steady progress for NXC-201, its lead CAR-T candidate in clinical development to address amyloid light chain amyloidosis (ALA). During the quarter, Immix announced... ► Artikel lesen | ||
| 19.05. | AAC Clyde Space - Steady start and no change to full year guidance | 324 | AAC Clyde Space's first quarter demonstrated a solid start to the year, within the normal volatility of this long lead time business. Key for investors is the build-out of low Earth orbit constellations... ► Artikel lesen | ||
| 16.05. | Pan American Silver - Strong Q125, MAG Silver acquisition | 1.083 | Pan American Silver (PAAS) delivered strong quarterly results, with higher commodity prices boosting revenues and lowering costs. Q125 EBITDA was US$330m, just 5% shy of the seasonally strongest Q4... ► Artikel lesen | ||
| 16.05. | VinaCapital Vietnam Opportunity Fund - Vietnam is affected by global uncertainty | 287 | Over the 12 months to end-March 2025, VinaCapital Vietnam Opportunity Fund (VOF) reported a 4.7% decline in NAV per share on a sterling total return (TR) basis, driven predominantly by profit taking... ► Artikel lesen | ||
| 15.05. | PVA TePla - Progress with metrology qualification | 420 | PVA TePla (PVA) reported Q125 results in which the expected step up in opex is already visible, resulting in lower EBITDA and EBIT. The industrial segment performed strongly, as did metrology, but crystal... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .